Merriman Curhan Ford Reiterates a 'Buy' on Repligen (RGEN); Slow & Steady Wins The Race
Merriman Curhan Ford reiterates a 'Buy' on Repligen Corporation (RGEN), raises price target range to $12-13 from $11-12.
Merriman analyst says, "Repligen has spent the last several years slowly and methodically putting in place a pipeline of therapeutic candidates at various stages of development (from preclinical to Phase III). A very important concept, which we feel sometimes slips the radar screens of investors, is that all the expenses associated with these candidates have been greatly offset or subsidized by both product and royalty revenue. We believe that slow and steady will win the race for the company as it looks to bring meaningful therapeutic candidates to market...Our valuation range is obtained using a sum of the parts analysis including our clinical NPV of the pipeline and an NPV of the company’s product revenue and royalty streams from Protein A and Orencia, respectively."
To see more analyst ratings on RGEN Click Here.
Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system.
Merriman analyst says, "Repligen has spent the last several years slowly and methodically putting in place a pipeline of therapeutic candidates at various stages of development (from preclinical to Phase III). A very important concept, which we feel sometimes slips the radar screens of investors, is that all the expenses associated with these candidates have been greatly offset or subsidized by both product and royalty revenue. We believe that slow and steady will win the race for the company as it looks to bring meaningful therapeutic candidates to market...Our valuation range is obtained using a sum of the parts analysis including our clinical NPV of the pipeline and an NPV of the company’s product revenue and royalty streams from Protein A and Orencia, respectively."
To see more analyst ratings on RGEN Click Here.
Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
